Partnership hopes to revolutionise treatment of spinal cord injuries

Spinal injury

Terebellum and NeurosolvTherapeutics will partner to launch Perineline, a new patented two-part therapy for spinal cord injuries. 

The drug has attained EMA Orphan Designation and it is hoped that it will revolutionise the therapeutic treatment and resulting end patient outcomes from spinal cord injuries.  

Terebellum will contribute strategic guidance in the pre-commercialisation stage, market access expertise, and supply chain logistics including distribution and fulfilment. 

Aidan Lynch, Chairman and Chief Executive Officer, NeursolvTherapeutics, said: “We are excited to work with Terebellum to bring Perineline to market globally, to allow us to proliferate and enable ethically controlled patient access under spinal cord trauma consultants. 

NeursolvTherapeutics selected Terebellum based upon its strategic insights for early-stage products, bench market access expertise throughout Europe and the United States, supply chain logistics and exclusive distribution and fulfilment services. 

Craig Caceci, Executive Vice President and Managing Director, Terebellum, added: “We look forward to working closely with NeursolvTherapeutics in a successful product launch that establishes optimal pricing and ensures seamless product access for patients with spinal cord injuries. This is an exciting time to be introducing a game-changing therapeutic treatment.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free